Sierra Bancorp reports higher net income
Sierra Bancorp, parent company of the Bank of the Sierra, had diluted earnings per share of 41 cents for the third quarter of 2017, the company announced in its earnings report on Oct. 23. In a news release, the company said it had consolidated net income of $5.7 million for the third quarter of 2017 Read More →
Read More →
Revenue, net income soar at The Trade Desk
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →MindBody revenues up but net losses continue
Consistent with its last earnings report, MindBody’s revenues increased 31 percent for its second fiscal quarter 2017, but net losses persisted, reaching $4.4 million, or 10 cents per basic and diluted share. The San Luis Obispo-based software provider for the wellness industry brought in $44.1 million in revenue, including $17.6 million from its payments software. Read More →
Read More →Semtech earnings fall short of analyst estimates
Semtech announced first quarter 2018 earnings of $11.8 million June 1, a 71 percent increase over the previous first quarter for earnings per share of 18 cents — missing analyst estimates ranging from 28 to 41 cents per share. Net sales rose 9.6 percent to $143.8 million during the quarter ended April 30, after deducting Read More →
Read More →Interlink net income grows on higher revenues
Story updated at 11 a.m. March 6: Interlink Electronics reported a 67 percent year-over-year increase in net income March 3, bringing in $924,000 for the fourth quarter 2016 and $2.89 million for the year. Revenues were almost flat to the fourth quarter of 2015 at $2.78 million, while fiscal year revenues increased 13 percent to Read More →
Read More →Stellar Biotechnologies gets immunotherapy manufacturing contract
Port Hueneme immunotherapy company Stellar Biotechnologies announced an exclusive multi-year supply agreement with Taiwanese manufacturer Amaran Biotechnology. The agreement coincides with late-stage clinical studies for an immunotherapy called Adagloxad Simolenin, which treats cancers including metastatic breast cancer. The two companies will also develop the manufacturing process for Stellar’s Keyhole Limpet Hemocyanin conjugated vaccine, made from Read More →
Read More →CalAmp misses analyst estimates for second quarter
CalAmp fell short of revenue and earnings per share estimates for the second quarter, the company reported Sept. 29. Net income was $521,000, which was down from $3.4 million in the second quarter of 2015. CalAmp posted revenues of $90.5 million, up from revenues of $69.8 million during the same quarter in 2015 but just Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
